RecruitingNot ApplicableNCT06993922

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy


Sponsor

Ain Shams University

Enrollment

50 participants

Start Date

May 29, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

  • Age from 18 to 65 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Undergoing supratentorial elective planned craniotomies.

Exclusion Criteria7

  • Patients refusal.
  • History of known allergy to the used local anesthetic or dexmedetomidine.
  • Bleeding disorders.
  • Evidence of local infection at the site of injection.
  • Emergency craniotomy.
  • Psychotic disorder.
  • Patients who will not be extubated in the operating room after surgery.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERScalp block

Patients will receive a scalp block with bupivacaine alone.

OTHERScalp block + Dexmedetomidine

Patients will receive a scalp block with dexmedetomidine as an adjuvant to bupivacaine.


Locations(1)

Ain Shams University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06993922


Related Trials